Europe Plunks $115M Into J&J Ebola Vaccine Research
Johnson & Johnson subsidiary Janssen Pharmaceuticals Co. will receive €100 million ($115.8 million) from a European Union-backed venture to develop a vaccine for the currently incurable Ebola virus that has been...To view the full article, register now.
Already a subscriber? Click here to view full article